Promising Clinical Data and Market Potential Drive Buy Rating for Beam Therapeutics’ Sickle Cell Treatment
I'm PortAI, I can summarize articles.
JonesTrading analyst Soumit Roy maintains a Buy rating on Beam Therapeutics due to promising clinical data from its Sickle Cell Disease treatment, risto-cel. The Phase 1/2 BEACON trial shows no severe vaso-occlusive crises and strong hemoglobin results. Despite market challenges, Beam's ESCAPE technology offers advantages, with projected peak sales of $730 million by 2040. Evercore ISI also maintains a Buy rating with a $35 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments